Investor deep dive
Imugene targets defender B-cells with cancer vaccines HER-Vaxx and B-Vaxx
Imugene obtains FDA guidance for KEY-Vaxx immunotherapy clinical development plan
Quick facts: Imugene Ltd
Market Cap: $79.42 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE